Identification of Commercially Available Oligonucleotide Starting Materials Directly Through Containers

Importance of the Topic

Rapid and reliable identification of raw materials is critical to ensure the safety and efficacy of oligonucleotide-based diagnostics and therapeutics. Phosphoramidite building blocks, used to synthesize short DNA/RNA sequences, must be verified under current Good Manufacturing Practice (cGMP) to prevent the introduction of incorrect or substandard reagents. Handheld Raman spectroscopy, particularly spatially offset Raman spectroscopy (SORS), offers a noninvasive approach to authenticate these materials directly through containers, streamlining quality control in pharmaceutical warehouses.

Objectives and Study Overview

This application note evaluates the Agilent Vaya handheld SORS Raman spectrometer for the direct identification of commercially available phosphoramidites through amber glass bottles. The goals are to demonstrate compliance with pharmacopeial guidelines, confirm selectivity among closely related analogs, and assess method development, validation, and deployment in a cGMP environment.

Instrumentation Used

• Agilent Vaya handheld Raman spectrometer with SORS capability
• Amber glass containers supplied by phosphoramidite manufacturers
• Software modules for method development, validation, system check, and audit trail

Methodology

Identification methods were built using ten replicate scans of each phosphoramidite in its original amber bottle. SORS measurements involve two acquisitions: a zero-offset spectrum rich in container signal and an offset spectrum emphasizing the sample. Subtraction yields a container-free fingerprint, which is matched against a spectral library. Methods were challenged with both expected substances and closely related analogs to fine-tune decision thresholds based on a two-score engine—correlation coefficient (R²) and linear model coefficient (LMC). Validation followed pharmacopeial recommendations (USP <1225>, ICH Q2), and the system check module ensured ongoing instrument performance per USP <858> and EP 2.2.48.

Main Results and Discussion

Overlay of container-corrected spectra revealed distinct Raman bands in the 1,000–1,500 cm⁻¹ region for most phosphoramidites. Three analogs exhibited highly similar profiles, initially leading to false positives in the challenge matrix. By incorporating spectra of these analogs into each method, the algorithm adjusted thresholds automatically and eliminated cross-identification. Performance qualification via the built-in system check confirmed compliance with wavelength accuracy, photometric precision, and laser power specifications.

Benefits and Practical Applications

• Noninvasive, direct-through-container testing eliminates sampling and reduces contamination risk
• Sub-minute identification accelerates material receipt and release into production
• Wizard-based workflows enable operation by nontechnical warehouse personnel
• Full audit trail and 21 CFR Part 11 compliance facilitate regulatory submissions
• High specificity differentiates target phosphoramidites from structurally related impurities or analogs

Future Trends and Applications

Advances in portable spectroscopy and chemometric algorithms will expand direct-through-container identification to a wider range of biopharmaceutical intermediates and excipients. Integration of machine learning models may further enhance selectivity and reduce model building time. Cloud-based spectral libraries and real-time data sharing could streamline global supply chain verification. Emerging handheld technologies may also enable in-line monitoring of critical raw materials during manufacturing.

Conclusion

The Agilent Vaya handheld SORS Raman system provides a rapid, accurate, and pharmacopeia-compliant solution for identifying phosphoramidite starting materials directly through amber bottles. Its robust method development, built-in validation workflow, and ease of use make it a valuable tool for accelerating cGMP raw material release and ensuring therapeutic quality.

References

1. USP <1858> Raman Spectroscopy–Theory and Practice.
2. European Pharmacopeia Chapter EP 2.2.48 Raman Spectroscopy.
3. Chinese Pharmacopeia General Rule Section 0421 Raman Spectroscopy.
4. Japanese Pharmacopeia Supplement II, JP XVII Section 2.26 Raman Spectroscopy.
5. ICH Q11 Guideline on Development and Manufacture of Drug Substances.